vs
STANDARD BIOTOOLS INC.（LAB）与SOUNDTHINKING, INC.（SSTI）财务数据对比。点击上方公司名可切换其他公司
SOUNDTHINKING, INC.的季度营收约是STANDARD BIOTOOLS INC.的1.3倍（$24.8M vs $19.6M），SOUNDTHINKING, INC.净利率更高（-11.2% vs -177.4%，领先166.2%），SOUNDTHINKING, INC.同比增速更快（5.9% vs -11.5%），SOUNDTHINKING, INC.自由现金流更多（$3.7M vs $-23.1M），过去两年SOUNDTHINKING, INC.的营收复合增速更高（-1.2% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
SoundThinking Inc.是一家公共安全技术供应商，主打声学监测解决方案，尤以枪支探测系统知名。该公司面向执法机构、市政部门和公共安全组织提供数据驱动的工具与分析服务，助力提升应急响应效率与社区安全水平。
LAB vs SSTI — 直观对比
营收规模更大
SSTI
是对方的1.3倍
$19.6M
营收增速更快
SSTI
高出17.4%
-11.5%
净利率更高
SSTI
高出166.2%
-177.4%
自由现金流更多
SSTI
多$26.8M
$-23.1M
两年增速更快
SSTI
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $24.8M |
| 净利润 | $-34.7M | $-2.8M |
| 毛利率 | 48.5% | 50.9% |
| 营业利润率 | -168.5% | -10.2% |
| 净利率 | -177.4% | -11.2% |
| 营收同比 | -11.5% | 5.9% |
| 净利润同比 | -28.8% | 32.0% |
| 每股收益（稀释后） | $-0.09 | $-0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABSSTI
| Q4 25 | — | $24.8M | ||
| Q3 25 | $19.6M | $25.1M | ||
| Q2 25 | $21.8M | $25.9M | ||
| Q1 25 | $40.8M | $28.3M | ||
| Q4 24 | — | $23.4M | ||
| Q3 24 | $22.1M | $26.3M | ||
| Q2 24 | $22.5M | $27.0M | ||
| Q1 24 | $45.5M | $25.4M |
净利润LABSSTI
| Q4 25 | — | $-2.8M | ||
| Q3 25 | $-34.7M | $-2.0M | ||
| Q2 25 | $-33.5M | $-3.1M | ||
| Q1 25 | $-26.0M | $-1.5M | ||
| Q4 24 | — | $-4.1M | ||
| Q3 24 | $-26.9M | $-1.4M | ||
| Q2 24 | $-45.7M | $-752.0K | ||
| Q1 24 | $-32.2M | $-2.9M |
毛利率LABSSTI
| Q4 25 | — | 50.9% | ||
| Q3 25 | 48.5% | 54.3% | ||
| Q2 25 | 48.8% | 53.3% | ||
| Q1 25 | 48.4% | 58.5% | ||
| Q4 24 | — | 50.0% | ||
| Q3 24 | 54.9% | 58.0% | ||
| Q2 24 | 46.1% | 59.6% | ||
| Q1 24 | 53.1% | 58.6% |
营业利润率LABSSTI
| Q4 25 | — | -10.2% | ||
| Q3 25 | -168.5% | -8.2% | ||
| Q2 25 | -118.1% | -11.4% | ||
| Q1 25 | -80.8% | -4.2% | ||
| Q4 24 | — | -17.7% | ||
| Q3 24 | -120.9% | -4.0% | ||
| Q2 24 | -134.5% | -0.2% | ||
| Q1 24 | -132.2% | -10.3% |
净利率LABSSTI
| Q4 25 | — | -11.2% | ||
| Q3 25 | -177.4% | -8.1% | ||
| Q2 25 | -153.7% | -12.1% | ||
| Q1 25 | -63.8% | -5.2% | ||
| Q4 24 | — | -17.4% | ||
| Q3 24 | -122.0% | -5.5% | ||
| Q2 24 | -203.3% | -2.8% | ||
| Q1 24 | -70.6% | -11.4% |
每股收益（稀释后）LABSSTI
| Q4 25 | — | $-0.22 | ||
| Q3 25 | $-0.09 | $-0.16 | ||
| Q2 25 | $-0.09 | $-0.24 | ||
| Q1 25 | $-0.07 | $-0.12 | ||
| Q4 24 | — | $-0.32 | ||
| Q3 24 | $-0.07 | $-0.11 | ||
| Q2 24 | $-0.12 | $-0.06 | ||
| Q1 24 | $-0.27 | $-0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $15.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $72.2M |
| 总资产 | $539.6M | $135.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABSSTI
| Q4 25 | — | $15.8M | ||
| Q3 25 | $129.4M | $11.8M | ||
| Q2 25 | $158.6M | $8.9M | ||
| Q1 25 | $150.9M | $11.7M | ||
| Q4 24 | — | $13.2M | ||
| Q3 24 | $210.6M | $15.3M | ||
| Q2 24 | $269.8M | $9.8M | ||
| Q1 24 | $287.1M | $8.5M |
总债务LABSSTI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABSSTI
| Q4 25 | — | $72.2M | ||
| Q3 25 | $399.7M | $73.5M | ||
| Q2 25 | $424.5M | $74.5M | ||
| Q1 25 | $454.6M | $73.8M | ||
| Q4 24 | — | $72.4M | ||
| Q3 24 | $489.3M | $73.3M | ||
| Q2 24 | $510.3M | $75.6M | ||
| Q1 24 | $577.3M | $74.8M |
总资产LABSSTI
| Q4 25 | — | $135.8M | ||
| Q3 25 | $539.6M | $134.4M | ||
| Q2 25 | $557.0M | $134.8M | ||
| Q1 25 | $579.6M | $136.3M | ||
| Q4 24 | — | $136.8M | ||
| Q3 24 | $681.5M | $141.7M | ||
| Q2 24 | $708.7M | $145.9M | ||
| Q1 24 | $777.7M | $145.0M |
负债/权益比LABSSTI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $4.5M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $3.7M |
| 自由现金流率自由现金流/营收 | -118.1% | 14.9% |
| 资本支出强度资本支出/营收 | 4.5% | 3.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $4.9M |
8季度趋势，按日历期对齐
经营现金流LABSSTI
| Q4 25 | — | $4.5M | ||
| Q3 25 | $-22.2M | $6.2M | ||
| Q2 25 | $-20.7M | $-1.3M | ||
| Q1 25 | $-30.3M | $-141.0K | ||
| Q4 24 | — | $-859.0K | ||
| Q3 24 | $-27.9M | $13.7M | ||
| Q2 24 | $-39.0M | $4.4M | ||
| Q1 24 | $-62.5M | $5.0M |
自由现金流LABSSTI
| Q4 25 | — | $3.7M | ||
| Q3 25 | $-23.1M | $4.9M | ||
| Q2 25 | $-22.6M | $-2.7M | ||
| Q1 25 | $-35.3M | $-1.0M | ||
| Q4 24 | — | $-2.2M | ||
| Q3 24 | $-30.1M | $12.4M | ||
| Q2 24 | $-41.0M | $2.8M | ||
| Q1 24 | $-63.3M | $2.8M |
自由现金流率LABSSTI
| Q4 25 | — | 14.9% | ||
| Q3 25 | -118.1% | 19.4% | ||
| Q2 25 | -103.6% | -10.3% | ||
| Q1 25 | -86.6% | -3.7% | ||
| Q4 24 | — | -9.5% | ||
| Q3 24 | -136.4% | 47.4% | ||
| Q2 24 | -182.2% | 10.5% | ||
| Q1 24 | -138.9% | 11.2% |
资本支出强度LABSSTI
| Q4 25 | — | 3.2% | ||
| Q3 25 | 4.5% | 5.5% | ||
| Q2 25 | 8.7% | 5.3% | ||
| Q1 25 | 12.4% | 3.2% | ||
| Q4 24 | — | 5.8% | ||
| Q3 24 | 10.2% | 4.7% | ||
| Q2 24 | 8.6% | 5.9% | ||
| Q1 24 | 1.7% | 8.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
SSTI
暂无分部数据
